Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy

Abstract Background The level of hemoglobin A1c (HbA1c) might be associated with the severity of tumor hypoxia in patients with cancer. Here, we evaluated the association between the level of HbA1c and survival outcome in stage III non‐small cell lung cancer patients treated with radical radiotherap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Moonkyoo Kong, Yu Jin Lim
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	hemoglobin A1c locoregional recurrence lung cancer radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f5c9b5ee6000452d9e939c41d589bf5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5c9b5ee6000452d9e939c41d589bf5f
record_format	dspace
spelling	oai:doaj.org-article:f5c9b5ee6000452d9e939c41d589bf5f2021-11-14T23:28:25ZHemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy1759-77141759-770610.1111/1759-7714.14174https://doaj.org/article/f5c9b5ee6000452d9e939c41d589bf5f2021-11-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14174https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract Background The level of hemoglobin A1c (HbA1c) might be associated with the severity of tumor hypoxia in patients with cancer. Here, we evaluated the association between the level of HbA1c and survival outcome in stage III non‐small cell lung cancer patients treated with radical radiotherapy. Methods We retrospectively analysed the clinical data of 104 patients with lung cancer treated with radiotherapy. The HbA1c levels of all patients were checked 1 week before the start of radiotherapy. Survival outcomes were analysed according to the HbA1c level. Results The 1‐, 2‐, and 3‐year locoregional recurrence‐free survival rates were 88.3%, 68.8%, and 63.0%, respectively, in the patient group with HbA1c levels ≤6% and 75.5%, 54.4%, and 41.8%, respectively, in the patient group with HbA1c levels >6% (p = 0.015). The HbA1c level remained a significant prognostic factor for locoregional recurrence‐free survival on multivariable analysis (hazard ratio = 2.014, 95% confidence interval = 1.088–3.726, p = 0.026). Conclusions Pretreatment HbA1c level is a significant prognostic factor for locoregional recurrence‐free survival in patients with stage III non‐small cell lung cancer treated with radical radiotherapy. Routine monitoring of pretreatment HbA1c levels and aggressive glycemic control may be considered to prevent the development of locoregional recurrence in these patients.Moonkyoo KongYu Jin LimWileyarticlehemoglobin A1clocoregional recurrencelung cancerradiotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 22, Pp 3032-3038 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hemoglobin A1c locoregional recurrence lung cancer radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hemoglobin A1c locoregional recurrence lung cancer radiotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Moonkyoo Kong Yu Jin Lim Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
description	Abstract Background The level of hemoglobin A1c (HbA1c) might be associated with the severity of tumor hypoxia in patients with cancer. Here, we evaluated the association between the level of HbA1c and survival outcome in stage III non‐small cell lung cancer patients treated with radical radiotherapy. Methods We retrospectively analysed the clinical data of 104 patients with lung cancer treated with radiotherapy. The HbA1c levels of all patients were checked 1 week before the start of radiotherapy. Survival outcomes were analysed according to the HbA1c level. Results The 1‐, 2‐, and 3‐year locoregional recurrence‐free survival rates were 88.3%, 68.8%, and 63.0%, respectively, in the patient group with HbA1c levels ≤6% and 75.5%, 54.4%, and 41.8%, respectively, in the patient group with HbA1c levels >6% (p = 0.015). The HbA1c level remained a significant prognostic factor for locoregional recurrence‐free survival on multivariable analysis (hazard ratio = 2.014, 95% confidence interval = 1.088–3.726, p = 0.026). Conclusions Pretreatment HbA1c level is a significant prognostic factor for locoregional recurrence‐free survival in patients with stage III non‐small cell lung cancer treated with radical radiotherapy. Routine monitoring of pretreatment HbA1c levels and aggressive glycemic control may be considered to prevent the development of locoregional recurrence in these patients.
format	article
author	Moonkyoo Kong Yu Jin Lim
author_facet	Moonkyoo Kong Yu Jin Lim
author_sort	Moonkyoo Kong
title	Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
title_short	Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
title_full	Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
title_fullStr	Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
title_full_unstemmed	Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy
title_sort	hemoglobin a1c level is a prognostic factor for locoregional recurrence in stage iii non‐small cell lung cancer patients treated with radiotherapy
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/f5c9b5ee6000452d9e939c41d589bf5f
work_keys_str_mv	AT moonkyookong hemoglobina1clevelisaprognosticfactorforlocoregionalrecurrenceinstageiiinonsmallcelllungcancerpatientstreatedwithradiotherapy AT yujinlim hemoglobina1clevelisaprognosticfactorforlocoregionalrecurrenceinstageiiinonsmallcelllungcancerpatientstreatedwithradiotherapy
_version_	1718429021590519808

Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non‐small cell lung cancer patients treated with radiotherapy

Ejemplares similares